Table 2.
University of Rochester Medical Center evidence-based transfusion guideline
Product | Clinical Indication | Transfusion Trigger |
---|---|---|
Red blood cells | Anemia | Hct <21%; Hgb <7 g/dL |
Anemia with acute coronary syndromes | Hct <24%; Hgb <8 g/dL | |
Platelets | High risk of bleeding | Platelet count <10,000 |
Fever or sepsis | Platelet count<20,000 | |
Acute bleeding | Platelet count<50,000 | |
Intracranial hemorrhage | Platelet count<100,000 | |
Documented platelet dysfunction | Per platelet function test | |
Plasma | Urgent need for warfarin reversal | INR >1.7 |
Clinical coagulopathy | Based on relevant laboratory and TEG values | |
Acute bleeding | To maintain the RBC to plasma ratio of our MTP | |
Plasma exchange for TTP | ||
Factor V or XI deficiency | ||
Cryoprecipitate | Low fibrinogen level | <150 and bleeding |
Documented dysfibrinogenemia | Clinically significant bleeding without obvious causation | |
Uremic coagulopathy unresponsive to DDAVP | ||
Factor VIII deficiency |
Abbreviations: DDAVP, desmopressin; Hct, hematocrit; Hgb, hemoglobin; INR, international normalized ratio; MTP, massive transfusion policy; TEG, thromboelastography; TTP, thrombotic thrombocytopenic purpura.